

Medical Faculty Martin-Luther-University Halle-Wittenberg

April 28th - 30th 2016

Workshop & Symposium

"Tumor Immunology meets Oncology XII"

Institute of Medical Immunology Prof. Dr. Barbara Seliger









SCIENTIFIC PROGRAM

Workshop program "Tumor immunology"

Date: 28th of April 2016

Venue: Auditorium, Magdeburger Str. 24, Halle, Germany

12.00 - 12.15 p.m.

Introduction:

Barbara Seliger

Session: News of tumor immunology Chair: Joerg Wischhusen / Annette Paschen

12.15 - 12.30 p.m.

Effect of mast cells and their soluble mediators on the *in vitro* proliferation of ovarian cancer cells Christine Weißenborn (Magdeburg, GER)

12.30 - 12.45 p.m.

Arginase activity in the blood and tissue of breast cancer patients in Ethiopia

Tamrat Abebe Zeleke (Addis Ababa, ETH)

12.45 - 01.00 p.m.

Detection of interleukin-23-expressing 6-sulfo LacNAc dendritic cells in colon cancer Rebekka Wehner (Dresden, GER)

01.00 – 01.15 p.m.

Clinical *in vivo* application and transcriptional *in vitro* characterization of designer DCs for therapeutic vaccination of melanoma

Stefanie Hoyer (Erlangen, GER)

01.15 - 01.30 p.m.

Development of tri-specific immunoligands to harness NK cell effector functions towards tumor cells Goekçen Goezuem (Cologne, GER)

01.30 - 01.45 p.m.

Targeted NK cells display potent activity against glioblastoma and induce protective antitumor immunity Congcong Zhang (Frankfurt, GER)

01.45 - 02.00 p.m.

Natural polymer X: a novel adjuvant to explore new antitumor vaccination strategies Anna Dalla Pietà (Padua, I)

02.00 - 02.15 p.m.

Development of CD4⁺ T cell resistance in the course of melanoma progression culminates in total T cell resistance in the context of MHC class I deficiency Christina Heeke (Essen, GER)

02.15 - 02.30 p.m.

Selenium meets tumor immunology and oncology Claudia Lennicke (Halle, GER)

02.30 - 02.45 p.m.

A thiol-disulfide switch in the regulation of cytoskeletal dynamics

Manuela Gellert (Greifswald, GER)

02.45 - 03.00 p.m.

Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy Kevin Leone (Padua, I)

03.00 - 03.30 p.m. Coffee break

Session: Methods and more news

Chair: Elfriede Noessner / Marc Schmitz

03.30 - 03.45 p.m.

Targeting simultaneously non-mutated HLA.A2-restricted MDM2 and p53 tumor-associated antigens as a novel double-edged sword approach for TCR gene therapy for multiple myeloma

Eva Amann (Mainz, GER)

03.45 - 04.00 p.m.

Identifying targets to eradicate acute myeloid leukemia stem cells

Carolin Pabst (Halle, GER)

04.00 - 04.15 p.m.

Redirection of human T cells to EGFR expressing tumor cells *via* a novel universal chimeric antigen receptor system

Susann Albert (Dresden, GER)

04.15 - 04.30 p.m.

"Two more powerful than one? - How two CARs modulate redirected T cell activation"
Astrid Holzinger (Cologne, GER)

04.30 - 05.00 p.m.

Immunophenotype and antigenomes of solid tumor therapies

Zlatko Trajanoski (Innsbruck, A)

05.00 - 05.20 p.m.

Imaging in cancer immunology research: phenotyping of multiple immune cell subsets in FFPR tissue Bjoern Wendik (PerkinElmer, Rodgau, GER)

05.20 - 05.40 p.m.

Blood based pre-treatment testing for checkpoint inhibitor efficacy

Heinrich Roeder (Biodesix, Boulder, USA)

05.40 - 06.00 p.m.

High-content protein profiling - cancer biomarkers, pathway profiling and disease mechanisms Christoph Schroeder (Sciomics, Heidelberg, GER)

Summary: Barbara Seliger

Symposium program "Tumor immunology"

Date: 29th of April 2016

Venue: Auditorium, Magdeburger Str. 24, Halle, Germany

09.00 a.m.

Welcome and introduction Barbara Seliger, Michael Gekle

Session: Immune signatures and biomarkers Chair: Guenther Haemmerling / Olivera Finn

09.15 - 09.45 a.m.

A universal cancer vaccine alternative to personalized cancer vaccine strategies
Bernhard Fox (Portland, USA)

09.45 - 10.15 a.m.

Identification of genetic determinants of anti-tumor immune responses using system biology approaches Davide Bedognetti (Doha, Q)

10.15 - 10.45 a.m.

On the identification of prognostic and predictive biomarkers in breast and prostate cancers Constantin Baxevanis (Athens, GR)

10.45 - 11.15 a.m. Coffee break

Session: Effector cells and immune responses Chair: Bernhard Fox / Samir Khleif

11.15 - 11.45 a.m.

The immunogenicity of breast cancer Pierre Coulie (Brussels, BE)

11.45 - 12.15 p.m.

What T cells see on human cancer! Pia Kvistborg (Amsterdam, NL)

12.15 - 12.45 p.m.

Oncobacteria: treatment of tumors with bacteria Ofer Mandelboim (Jerusalem, IL) 12.45 - 01.00 p.m.

Identification of a new human natural killer cell population

Jacques Zimmer (Luxemburg, L)

01.00 - 01.45 p.m. Lunch break

Special lecture

Chair / Introduction: Barbara Seliger

01.45 - 2.15 p.m.

Cancer immune surveillance and immune prevention Olivera Finn (Pittsburgh, USA)

Session: Immune escape and immune modulation Chair: Ofer Mandelboim / Patrick Michl

02.15 - 02.45 p.m.

Epigenetic modulation of the immune suppressive tumor network

Gosse Adema (Nijmegen, NL)

02.45 - 03.15 p.m.

Role of the metabolism in immune surveillance and escape of tumors

Barbara Seliger (Halle, GER)

03.15 - 03.45 p.m.

Immune modulatory activity of non-cytotoxic chemotherapy

Angus Dalgleish (London, UK)

03.45 - 04.15 p.m. Coffee break

Session: Tumor microenvironment and immunity Chair: D. Riemann / Pierre Coulie

04.15 - 04.45 p.m.

Control of tumor immunity by innate cells in the tumor microenvironment

Guenther Haemmerling (Heidelberg, GER)

04.45 - 05.15 p.m.

Enhancing anti-tumor immunity and neutralization of immune suppression in the tumor microenvironment Suzanne Ostrand-Rosenberg (Philadelphia, USA)

05.15 - 05.45 p.m.

Circulating myeloid cells and exosomes: a window to patient's immune suppression Licia Rivoltini (Milano, I)

Symposium program "Tumor immunology"

Date: 30th of April 2016

Venue: Auditorium, Magdeburger Str. 24, Halle, Germany

Session: Novel immunotherapeutic strategies and monitoring

monitoring

Chair: Thomas Tueting / Licia Rivoltini

08.30 - 09.00 a.m.

Targeting infiltrating myeloid cells in pancreatic cancer - a new therapeutic option?
Patrick Michl (Halle, GER)

09.00 - 9.30 a.m.

Outsourcing cancer immunity Johanna Olweus (Oslo, NOR)

09.30 - 10.00 a.m.

Combination therapy of checkpoint blockade in malignant mesothelioma
Luana Calabrò (Siena, I)

10.00 - 10.30 a.m.

Prediction of response to check point inhibitors Giuseppe Curigliano (Milano, I)

10.30 - 11.00 a.m. Coffee break

Session: Combination therapy Chair: Constantin Baxevanis / Suzanne Ostrand-Rosenberg

11.00 - 11.30 a.m.

TKI, immune modulators and a component of immune therapy
Samir Khleif (Augusta, USA)

11.30 - 12.00 a.m.

Combining T cell immunotherapy and signal transduction inhibitors for the treatment of melanoma Thomas Tueting (Magdeburg, GER)

12.00 - 12.30 p.m.

Improving the efficacy of cancer immunotherapy by vascular checkpoint blockade
Joerg Wischhusen (Wuerzburg, GER)

12.30 - 12.45 p.m.

Wrap up and closing remarks



REGISTRATION FEE:

150 € - payable until 21st of April 2016 or cash at the registration desk - Vouchers are required for registration. MLU members will be charged for $50 \, \text{€}$, students for free Registration can be waived in special cases (Please bring in your MLU/UKH ID card)

Bank name:

Deutsche Apotheker- und Aerztebank IBAN: DE46300606011008814171

SWIFT code: DAAEDEDD

reason for payment: name, reg. fee TIMO XII

SYMPOSIUM SECRETARY:

Sylvi Magdeburg
Institute of Medical Immunology
Martin Luther University Halle-Wittenberg
Magdeburger Straße 2, 06097 Halle (Saale)
Tel. +49 (0) 345 557 5041 / or -1357
Fax +49 (0) 345 557 4055
e-mail: immunologie@uk-halle.de

The Medical Association of Saxony-Anhalt credits this educational activity with 7 points (workshop) and 12 points (symposium). You will receive a certificate of attendance on site at the registration desk.



WE THANK OUR SPONSORS:

Astra Zeneca GmbH (1.500 €), Beckman Coulter GmbH, Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000 €), City of Halle, Epiontis GmbH, Deutsche Forschungsgemeinschaft (DFG), Deutsche Gesellschaft für Immunologie (DGfI), Essen BioScience Ltd, Life Science Solutions PerkinElmer, Lipocalyx GmbH, Miltenyi Biotec GmbH, nanoString Technologies, Novartis Pharma GmbH (750 €), Pfizer Pharma GmbH (1.000 €), Sarstedt, Sciomics GmbH, SERVA GmbH, Society for Immunotherapy of Cancer











































2 - Lecture HallMagdeburger Straße 24

21 - Institute of Medical Immunology Magdeburger Straße 2

CONFERENCE VENUE:

Martin-Luther-University Medical Faculty Magdeburger Straße 24, 06112 Halle

Lecture Hall MS24-HS

Airport or main train station transportation:

Various taxi companies service the airport Leipzig or the main train station Halle. A cab ride costs approx. $45 \in$ from the airport to the clinic and from the train station to the Conference venue approx. $8 \in$. In addition, public train service is available from the airport to Halle (every 30 min.).

From the main train station in Halle you can take the tram no. 2, 5 or 12 direction Soltauer Straße, Kroellwitz or Trotha for two stops.

PARKING INFORMATION:

Several parking facilities are located at the Magdeburger Str. 24, enter the main entrance of the hospital.

PHOTOS:

Photos by © Michael Hoetzel, DGPh

in cooperation with the









Institute of Medical Immunology Prof. Dr. Barbara Seliger Director of FOCIS Center of Excellence

Martin-Luther-University Halle-Wittenberg
Medical Faculty
Magdeburger Straße 2
06112 Halle (Saale)

Tel. +49 (0) 345 557 5041 / or -1357 Fax +49 (0) 345 557 4055

e-mail: immunologie@uk-halle.de